​

Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ionis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$787.65M

Latest Revenue (Q)

$225.25M

Main Segment (Y)

Research and Development Revenue

Ionis Pharmaceuticals Revenue by Period

Ionis Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$787.65M34.18%
2022-12-31$587.00M-27.53%
2021-12-31$810.00M11.11%
2020-12-31$729.00M-35.08%
2019-12-31$1.12B87.27%
2018-12-31$599.67M18.12%
2017-12-31$507.67M46.46%
2016-12-31$346.62M22.18%
2015-12-31$283.70M32.47%
2014-12-31$214.16M45.41%
2013-12-31$147.28M44.33%
2012-12-31$102.05M2.99%
2011-12-31$99.09M-8.65%
2010-12-31$108.47M-10.80%
2009-12-31$121.60M13.44%
2008-12-31$107.19M53.96%
2007-12-31$69.62M183.80%
2006-12-31$24.53M-38.87%
2005-12-31$40.13M-5.84%
2004-12-31$42.62M-14.73%
2003-12-31$49.99M-37.65%
2002-12-31$80.18M50.51%
2001-12-31$53.27M43.00%
2000-12-31$37.26M9.90%
1999-12-31$33.90M-13.52%
1998-12-31$39.20M20.62%
1997-12-31$32.50M43.81%
1996-12-31$22.60M73.85%
1995-12-31$13.00M28.71%
1994-12-31$10.10M-16.53%
1993-12-31$12.10M-

Ionis Pharmaceuticals generated $787.65M in revenue during NA 2023, up 34.18% compared to the previous quarter, and up 131.35% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$225.25M88.50%
2024-03-31$119.50M-63.18%
2023-12-31$324.50M125.35%
2023-09-30$144.00M-23.40%
2023-06-30$188.00M43.51%
2023-03-31$131.00M-13.82%
2022-12-31$152.00M-4.86%
2022-09-30$159.77M19.42%
2022-06-30$133.79M-5.73%
2022-03-31$141.92M-67.75%
2021-12-31$440.00M230.60%
2021-09-30$133.09M5.84%
2021-06-30$125.75M12.67%
2021-03-31$111.61M-61.51%
2020-12-31$290.00M81.16%
2020-09-30$160.08M9.99%
2020-06-30$145.54M9.13%
2020-03-31$133.37M-73.00%
2019-12-31$494.00M194.24%
2019-09-30$167.89M2.37%
2019-06-30$164.00M-44.82%
2019-03-31$297.21M54.71%
2018-12-31$192.11M32.13%
2018-09-30$145.40M23.48%
2018-06-30$117.75M-18.47%
2018-03-31$144.42M-16.18%
2017-12-31$172.30M42.50%
2017-09-30$120.91M16.09%
2017-06-30$104.15M-5.58%
2017-03-31$110.30M-31.21%
2016-12-31$160.35M44.55%
2016-09-30$110.93M188.35%
2016-06-30$38.47M4.33%
2016-03-31$36.87M-28.50%
2015-12-31$51.57M4.99%
2015-09-30$49.12M-59.21%
2015-06-30$120.43M92.43%
2015-03-31$62.58M-26.25%
2014-12-31$84.86M92.59%
2014-09-30$44.06M-22.80%
2014-06-30$57.08M102.68%
2014-03-31$28.16M-33.35%
2013-12-31$42.25M79.14%
2013-09-30$23.59M-38.08%
2013-06-30$38.09M-12.15%
2013-03-31$43.36M118.19%
2012-12-31$19.87M71.30%
2012-09-30$11.60M-75.49%
2012-06-30$47.34M103.74%
2012-03-31$23.23M-28.29%
2011-12-31$32.40M56.44%
2011-09-30$20.71M-16.56%
2011-06-30$24.82M17.38%
2011-03-31$21.15M-19.96%
2010-12-31$26.42M-7.70%
2010-09-30$28.62M21.79%
2010-06-30$23.50M-21.46%
2010-03-31$29.93M-7.24%
2009-12-31$32.26M20.51%
2009-09-30$26.77M-13.62%
2009-06-30$30.99M-1.85%
2009-03-31$31.58M52.83%
2008-12-31$20.66M-35.87%
2008-09-30$32.22M-2.26%
2008-06-30$32.96M54.36%
2008-03-31$21.35M-13.64%
2007-12-31$24.73M-

Ionis Pharmaceuticals generated $225.25M in revenue during Q2 2024, up 88.50% compared to the previous quarter, and up 171.95% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue Breakdown

Ionis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
SPINRAZA Royalties$240.38M$292.99M---
Licensing and Other Royalties$33.30M$30.99M$19.12M$8.12M$17.20M
Other Commercial$68.21M----
Product$34.91M$30.05M$70.00M$42.25M-
Research and Development Revenue$479.06M$284.01M---
Commercial$308.59M$303.36M$342.39M$364.70M$352.45M
Collaborative Agreement Revenue$352.66M$207.22M---
Spinraza Royalties-$242.31M$267.78M$286.58M-
Eplontersen Joint Development Revenue-$76.79M---
Research and Development Revenue Under Collaborative Agreements--$468.06M$364.56M$770.15M
TEGSEDI and WAYLIVRA--$55.50M--

Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Research and Development Revenue (31.58%), Collaborative Agreement Revenue (23.25%), Commercial (20.34%), SPINRAZA Royalties (15.84%), Other Commercial (4.50%), Product (2.30%), and Licensing and Other Royalties (2.19%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Dec 23Sep 23Jun 23
Other Commercial$13.15M$11.51M$34.50M$16.83M$16.89M
Licensing and Other Royalties$4.23M$3.32M$13.71M$8.54M-
Commercial$75.73M$72.04M$78.84M$84.08M$77.90M
SPINRAZA Royalties$57.21M$56.74M$112.11M$67.25M$61.01M
Research and Development Revenue$58.08M$153.21M$245.66M$60.13M$110.51M
Product$8.92M$8.19M$20.15M$8.29M-
Collaborative Agreement Revenue$44.88M$141.52M$179.14M$44.17M$91.01M
Eplontersen Joint Development Revenue---$15.96M$19.50M

Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Commercial (28.88%), Research and Development Revenue (22.15%), SPINRAZA Royalties (21.82%), Collaborative Agreement Revenue (17.12%), Other Commercial (5.02%), Product (3.40%), and Licensing and Other Royalties (1.61%).

Ionis Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
BMRNBioMarin Pharmaceutical$2.42B$733.87B
EXELExelixis$1.83B$478.06M
ALNYAlnylam Pharmaceuticals$1.83B$420.15M
SRPTSarepta Therapeutics$1.24B$362.93M
PTCTPTC Therapeutics$937.82M$135.42M
HALOHalozyme Therapeutics$829.25M$290.08M
IONSIonis Pharmaceuticals$787.65M$225.25M
APLSApellis Pharmaceuticals$366.28M$176.57M
KRYSKrystal Biotech$50.70M$83.84M
ARWRArrowhead Pharmaceuticals$3.55M-
IOVAIovance Biotherapeutics$1.19M$58.55M
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
AKROAkero Therapeutics--

IONS Revenue FAQ

What is Ionis Pharmaceuticals’s yearly revenue?

Ionis Pharmaceuticals's yearly revenue for 2023 was $787.65M, representing an increase of 34.18% compared to 2022. The company's yearly revenue for 2022 was $587M, representing a decrease of -27.53% compared to 2021. IONS's yearly revenue for 2021 was $810M, representing an increase of 11.11% compared to 2020.

What is Ionis Pharmaceuticals’s quarterly revenue?

Ionis Pharmaceuticals's quarterly revenue for Q2 2024 was $225.25M, a 88.50% increase from the previous quarter (Q1 2024), and a 19.81% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $119.5M, a -63.18% decrease from the previous quarter (Q4 2023), and a -8.78% decrease year-over-year (Q1 2023). IONS's quarterly revenue for Q4 2023 was $324.5M, a 125.35% increase from the previous quarter (Q3 2023), and a 113.49% increase year-over-year (Q4 2022).

What is Ionis Pharmaceuticals’s revenue growth rate?

Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -2.76%, and for the last 5 years (2019-2023) was -29.86%.

What are Ionis Pharmaceuticals’s revenue streams?

Ionis Pharmaceuticals's revenue streams in c 23 are SPINRAZA Royalties, Licensing and Other Royalties, Other Commercial, Product, Research and Development Revenue, Commercial, and Collaborative Agreement Revenue. SPINRAZA Royalties generated $240.38M in revenue, accounting 15.84% of the company's total revenue, down -17.96% year-over-year. Licensing and Other Royalties generated $33.3M in revenue, accounting 2.19% of the company's total revenue, up 7.44% year-over-year. Other Commercial generated $68.21M in revenue, accounting 4.50% of the company's total revenue Product generated $34.91M in revenue, accounting 2.30% of the company's total revenue, up 16.18% year-over-year. Research and Development Revenue generated $479.06M in revenue, accounting 31.58% of the company's total revenue, up 68.68% year-over-year. Commercial generated $308.59M in revenue, accounting 20.34% of the company's total revenue, up 1.73% year-over-year. Collaborative Agreement Revenue generated $352.66M in revenue, accounting 23.25% of the company's total revenue, up 70.18% year-over-year.

What is Ionis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Ionis Pharmaceuticals was Research and Development Revenue. This segment made a revenue of $479.06M, representing 31.58% of the company's total revenue.